07:00 , Aug 8, 2016 |  BC Week In Review  |  Company News

Inovio, Roche deal

Inovio said Roche is terminating a 2013 deal and returning exclusive, worldwide rights to Inovio’s INO-1800. Roche said the termination was a “strategic decision” and that the pharma will pay Inovio R&D costs per...
07:00 , Aug 3, 2016 |  BC Extra  |  Company News

Roche returning rights to Inovio's HBV vaccine

Inovio Pharmaceuticals Inc. (NASDAQ:INO) said Roche (SIX:ROG; OTCQX:RHHBY) is terminating a 2013 deal and is returning exclusive, worldwide rights to Inovio's hepatitis B vaccine INO-1800. Inovio expects data in 2H17 from an open-label Phase I...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Clinical News

TG1050: Phase I/Ib ongoing

Transgene said a safety review committee recommended continuation of a double-blind, placebo-controlled, international Phase I/Ib trial evaluating single injections and 3 once-weekly injections of TG1050 with standard antiviral therapy. The trial plans to enroll up...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

TG1050: Phase I/ Ib started

Transgene began a double-blind, placebo-controlled, international Phase I/Ib trial to evaluate single injections and 3 once-weekly injections of TG1050 with standard antiviral therapy in about 96 patients. The Phase I portion will enroll up to...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

Hepatitis B vaccine: Completed Phase IIb/III enrollment

Abivax completed enrollment of 266 patients with hepatitis B e antigen (HBeAg)-negative active chronic HBV infection in an open-label, international Phase IIb/III trial comparing 10 doses of subcutaneous ABX203 over 24 weeks plus nucleoside or...
01:23 , Jun 26, 2015 |  BC Extra  |  Financial News

Abivax prices EUR $57.7M IPO

Abivax S.A.S. (Euronext:ABVX) raised EUR 57.7 million ($65.3 million) through the sale of 2.7 million shares at EUR 21.30 in an upsized IPO on Euronext Paris. Underwriters were RBC Capital Markets; Swiss Life Banque Privee;...
07:00 , May 25, 2015 |  BC Week In Review  |  Clinical News

SynCon DNA HBV vaccine: Phase I started

Inovio began an open-label, dose-escalation, international Phase I trial evaluating INO-1800 alone or in combination with INO-9112, an IL-12-based immune activator, delivered by electroporation in 126 patients. The start triggered a $3 million milestone payment...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Clinical News

Hepatitis B vaccine: Phase IIb/III started

Abivax began an open-label, international Phase IIb/III trial to compare 10 doses of subcutaneous ABX203 over 24 weeks plus nucleoside or nucleotide analog therapy for 48 weeks vs. nucleoside or nucleotide analog therapy alone in...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Inovio, Roche deal

Inovio granted Roche exclusive, worldwide rights to prostate cancer vaccine INO-5150 and hepatitis B vaccine INO-1800, as well as use of Inovio's Cellectra electroporation technology to deliver the vaccines. Roche also...
00:54 , Sep 11, 2013 |  BC Extra  |  Company News

Inovio licenses preclinical immunotherapy vaccines to Roche

Inovio Pharmaceuticals Inc. (NYSE-M:INO) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to prostate cancer vaccine INO-5150 and hepatitis B vaccine INO-1800, as well as use of Inovio's Cellectra electroporation technology to deliver the vaccines. Roche...